These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 23994769)

  • 1. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
    Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
    Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo.
    Ma P; He Q; Li W; Li X; Han H; Jin M; Liu C; Tao H; Ma J; Gao B
    Oncol Rep; 2015 Nov; 34(5):2567-75. PubMed ID: 26323605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
    Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
    Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
    Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.
    Prasad S; Gaedicke S; Machein M; Mittler G; Braun F; Hettich M; Firat E; Klingner K; Schüler J; Wider D; Wäsch RM; Herold-Mende C; Elsässer-Beile U; Niedermann G
    Cancer Res; 2015 Jun; 75(11):2166-76. PubMed ID: 25840983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
    Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
    Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Killing activity of co-cultured cytokine-induced killer cells and dendritic cells against multi-drug resistant tumor cell lines].
    Li SJ; Zhang LS; Chai Y; Zhang YF; Zhang YM; Zeng PY; Wu CY
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):733-7. PubMed ID: 18396683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells.
    Zhang L; Hou Y; Zhang J; Hu J; Zhang K
    Oncol Lett; 2013 Jun; 5(6):1826-1832. PubMed ID: 23833649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
    Zhao L; Yang Y; Zhou P; Ma H; Zhao X; He X; Wang T; Zhang J; Liu Y; Zhang T
    J Immunother; 2015; 38(6):217-28. PubMed ID: 26049545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
    Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
    Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
    Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells.
    Jin ZH; Sogawa C; Furukawa T; Saito Y; Aung W; Fujibayashi Y; Saga T
    Mol Imaging; 2012; 11(6):445-50. PubMed ID: 23084245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.